# 2026年1月27日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 靶向癌症中的代谢-表观遗传-免疫轴：分子机制与治疗启示

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41582215)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41582215
**DOI：** 10.1038/s41392-025-02334-4

### 第一部分 原文与翻译

**英文原标题：** Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications.

> **英文摘要：**
> Cancer cells orchestrate a highly dynamic and interconnected network spanning metabolic, epigenetic, and immune mechanisms to drive adaptive plasticity and continuous development. This review synthesizes emerging insights into the coevolutionary strategies employed by malignant and stromal cells-particularly tumor cells and immune populations-across the continuum of tumorigenesis, metastasis, and treatment resistance. During tumor initiation, cancer cells rewire metabolism and generate oncometabolites that reshape the chromatin architecture to support immune evasion. Concurrently, metabolic competition in the tumor microenvironment (TME) induces epigenetic exhaustion of cytotoxic T cells, whereas tumor-associated myeloid cells adopt immunosuppressive and angiogenic phenotypes via metabolite-dependent histone modifications to promote carcinogenesis. At metastatic frontiers, under the local metabolic pressure of target organs, tumor cells undergo epigenetic reprogramming to evade immune attacks and support colonization. Premetastatic niches are preconditioned through exosome-mediated transfer of metabolic enzymes and noncoding RNAs that reprogram resident cells before tumor cells arrive. In cancer immunotherapy, tumors often exploit metabolic adaptative strategies to inhibit cell death signaling pathways or the compensatory activation of self-protective mechanisms to circumvent immune-mediated cytotoxicity and develop resistance to immunotherapy. By mapping these dynamic interactions, we propose a novel conceptual framework of the "metabolic-epigenetic-immune axis" that transcends traditional compartmentalized approaches and helps to identify nodal convergence points for therapeutic co-targeting. This review also prioritizes multitarget inhibitors arising from the convergence of metabolic reprogramming, epigenetic plasticity, and immune evasion networks. An integrated approach to these pathways advances next-generation precision oncology strategies aimed at circumventing the evolutionary resilience of cancer.

> **中文摘要：**
> 癌细胞通过协调一个涵盖代谢、表观遗传和免疫机制的高度动态且相互关联的网络，以驱动适应性塑性和持续发展。本综述综合了关于恶性细胞与基质细胞（特别是肿瘤细胞与免疫群体）在肿瘤发生、转移和治疗耐药全过程中的共进化策略的新兴见解。在肿瘤启动期间，癌细胞重构代谢并产生肿瘤代谢物，这些代谢物通过重塑染色质结构来支持免疫逃逸。同时，肿瘤微环境（TME）中的代谢竞争会诱导细胞毒性T细胞的表观遗传耗竭，而肿瘤相关骨髓细胞则通过代谢物依赖的组蛋白修饰采取免疫抑制和促血管生成表型，从而促进癌症发生。在转移前沿，在靶器官局部代谢压力的作用下，肿瘤细胞经历表观遗传重编程以逃避免疫攻击并支持定植。在肿瘤细胞到达之前，通过外泌体介导的代谢酶和非编码RNA转移，使转移前生态位（premetastatic niches）得到预处理，从而重编程驻留细胞。在癌症免疫治疗中，肿瘤通常利用代谢适应策略来抑制细胞死亡信号通路，或通过代偿性激活自我保护机制来规避免疫介导的细胞毒性并产生对免疫疗法的耐药性。通过绘制这些动态相互作用的图谱，我们提出了一个新颖的“代谢-表观遗传-免疫轴”概念框架，该框架超越了传统的模块化方法，并有助于识别用于治疗共同靶向的节点汇聚点。本综述还重点介绍了由代谢重编程、表观遗传塑性和免疫逃逸网络融合而产生的多靶点抑制剂。针对这些途径的整合方法推进了下一代精准肿瘤学策略，旨在规避癌症的进化韧性。

### 第二部分 AI 大师评价

本文系统性地提出了“代谢-表观遗传-免疫轴”这一整合性框架，深入探讨了癌细胞如何通过这三者的动态耦合来驱动肿瘤的发生、转移与免疫耐药。文章不仅揭示了代谢物通过重塑染色质结构诱导免疫抑制的具体分子机制，还重点分析了转移前生态位的预处理及免疫疗法耐药的代谢根源。其核心创新在于打破了单一维度的研究局限，提出通过多靶点抑制剂干扰轴向节点，为开发下一代精准肿瘤治疗方案提供了重要的理论支撑。

---

## 2. 肿瘤相关中性粒细胞的时空动态：弥合癌症进展与免疫治疗之间的鸿沟

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41582133)
**期刊：** Molecular cancer
**PMID：** 41582133
**DOI：** 10.1186/s12943-026-02570-4

### 第一部分 原文与翻译

**英文原标题：** Spatiotemporal dynamics of tumor-associated neutrophils: bridging the gap between cancer progression and immunotherapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文重点探讨了肿瘤相关中性粒细胞（TANs）在时间与空间维度上的动态演变过程，及其在调控肿瘤进展和免疫治疗响应中的关键作用。文章深入分析了TANs的异质性与可塑性，揭示了其如何作为连接基础肿瘤生物学与临床转化医学的关键桥梁。该综述旨在通过解析中性粒细胞的时空特性，为克服免疫治疗耐药性并开发新型联合治疗策略提供重要的理论依据。

---

## 3. 质子放射治疗低级别胶质瘤患者的认知功能、生活质量及生存结局：一项II期研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41581137)
**期刊：** Neuro-oncology
**PMID：** 41581137
**DOI：** 10.1093/neuonc/noag008

### 第一部分 原文与翻译

**英文原标题：** Cognitive Function, Quality of Life, and Survival Outcomes in Patients with Lower Grade Gliomas Treated with Proton Radiation Therapy: A Phase II study.

> **英文摘要：**
> BACKGROUND: Lower grade gliomas (LGGs) typically affect younger adults and are associated with long-term survival. Treatment-related toxicities, especially neurocognitive and neuroendocrine effects, are a concern. Proton therapy may reduce these risks by minimizing radiation exposure to healthy brain tissue. This study evaluates the safety and efficacy of proton therapy in LGG patients, focusing on neurocognitive, neuroendocrine, and quality-of-life (QOL) outcomes.
> 
> METHODS: This single-institution, prospective phase 2 trial enrolled 60 patients with WHO grade 1-2 gliomas or IDH-mutant grade 3 gliomas. Proton therapy was delivered at 54 Gy(RBE) or 59.4 Gy(RBE) by tumor grade. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), neurocognitive and neuroendocrine function, and QOL. Neurocognitive testing occurred at baseline and biennially. QOL was assessed using the FACT-Brain questionnaire. Toxicities were graded per CTCAE v4.0.
> 
> RESULTS: With a median follow-up of 7.0 years, 5-year PFS and OS were 79.1% and 85.6%, respectively. PFS was highest in IDH-mutant, 1p/19q co-deleted gliomas (100%) and lowest in IDH-wildtype tumors (62.5%). New neurocognitive deficits occurred in 26% of patients at 5 years. Neuroendocrine dysfunction occurred in 5.3%, with only one case attributed to radiation. QOL declined transiently at 6 months, with 15% showing clinically meaningful decline at 5 years. No late grade 3 toxicities were observed; one case of grade 4 radionecrosis occurred.
> 
> CONCLUSIONS: Proton therapy for LGG can offer effective disease control with modest long-term toxicity. These findings support its use as a standard radiation modality and highlight the need for comparative trials with photon therapy.

> **中文摘要：**
> 背景：低级别胶质瘤（LGGs）通常影响年轻成年人，并与长期生存相关。治疗相关的毒性，尤其是神经认知和神经内分泌影响，是一个备受关注的问题。质子治疗可能通过最大限度地减少对健康脑组织的辐射暴露来降低这些风险。本研究评估了质子治疗在低级别胶质瘤患者中的安全性和有效性，重点关注神经认知、神经内分泌和生活质量（QOL）结局。
> 
> 方法：这项单机构、前瞻性2期试验招募了60名WHO 1-2级胶质瘤或IDH突变3级胶质瘤患者。根据肿瘤分级，质子治疗的照射剂量为54 Gy(RBE)或59.4 Gy(RBE)。主要终点是无进展生存期（PFS）；次要终点包括总生存期（OS）、神经认知和神经内分泌功能以及生活质量。神经认知测试在基线和之后每两年进行一次。使用FACT-Brain问卷评估生活质量。毒性根据CTCAE v4.0标准进行分级。
> 
> 结果：中位随访时间为7.0年，5年PFS和OS分别为79.1%和85.6%。PFS在IDH突变且1p/19q共缺失的胶质瘤中最高（100%），在IDH野生型肿瘤中最低（62.5%）。5年时，26%的患者出现了新的神经认知缺陷。神经内分泌功能障碍发生率为5.3%，其中仅有一例归因于放射治疗。生活质量在6个月时出现暂时性下降，15%的患者在5年时表现出具有临床意义的下降。未观察到晚期3级毒性；发生了一例4级放射性坏死。
> 
> 结论：质子治疗低级别胶质瘤可以提供有效的疾病控制，且长期毒性适中。这些发现支持将其作为标准的放射治疗手段，并强调了开展与光子治疗对比试验的必要性。

### 第二部分 AI 大师评价

本研究通过一项中位随访时间长达7年的前瞻性II期试验，系统评估了质子放射治疗在低级别胶质瘤中的长期疗效及安全性。研究重点考察了患者的认知功能和生活质量，证明了质子治疗在维持良好疾病控制率的同时，具有较低的神经毒性和神经内分泌损伤风险。尽管其单臂研究设计存在一定的局限性，但其详实的长期随访数据为质子治疗保护脑功能提供了有力证据，具有重要的临床推广参考价值。

---

## 4. p16阳性肝细胞通过激活LIFR家族通路驱动肝纤维化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580988)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41580988
**DOI：** 10.1002/advs.202510562

### 第一部分 原文与翻译

**英文原标题：** p16-Positive Hepatocytes Drive Liver Fibrosis Through Activation of LIFR Family Pathway.

> **英文摘要：**
> As organs undergo the process of aging, they exhibit signs of progressive fibrosis, a hallmark of aging that is observed in various organs, including the liver, kidneys, and lungs. Liver fibrosis is a particularly deleterious outcome of the healing processes that occur during the repair of chronic liver injury. It is widely accepted that the majority of these injuries are initially triggered by hepatocytes. Indeed, elderly patients have been shown to be more prone to developing liver fibrosis following hepatic injury. However, the mechanisms by which aging promotes fibrotic processes remain to be elucidated. The preceding observation, indicating a robust correlation between the severity of fibrosis in human cirrhotic patients and the population of hepatocytes expressing elevated levels of p16 (p16), proposes that p16 hepatocytes might serve as initiators of fibrogenic processes in response to liver injury. In this study, we employed a CCl-induced hepatitis model to promote a fibrogenic process and observed the accumulation of p16 hepatocytes in zone 3. These p16 cells manifest numerous senescent characteristics, and their accumulation has been strongly correlated with the severity of liver fibrosis. Selective elimination of p16 hepatocytes has been shown to ameliorate CCl-induced liver fibrosis, presumably through the suppression of hepatic stellate cell activation. Single-cell transcriptomic analysis revealed that murine and human hepatocytes up-regulated Ctf1 or Lif, the ligands of the LIFR signaling pathway. The administration of LIFR ligands has been demonstrated to enhance the phosphorylation of STAT3, and the LIFR inhibitor rescued the fibrogenic phenotype in hepatic stellate cells induced by secreted factors from senescent hepatocytes. This finding offers potential therapeutic insights for the management of liver fibrosis.

> **中文摘要：**
> 随着器官经历衰老过程，它们会表现出进行性纤维化的迹象，这是在包括肝脏、肾脏和肺在内的多种器官中观察到的衰老标志。肝纤维化是慢性肝损伤修复过程中愈合过程产生的一种特别有害的结果。普遍认为，大多数此类损伤最初是由肝细胞触发的。事实上，研究表明老年患者在肝损伤后更容易发生肝纤维化。然而，衰老促进纤维化过程的机制仍有待阐明。此前的观察结果显示，人类肝硬化患者的纤维化严重程度与表达高水平p16（p16+）的肝细胞群之间存在强相关性，这表明p16阳性肝细胞可能是响应肝损伤的促纤维化过程的发起者。在本研究中，我们采用四氯化碳（CCl4）诱导的肝炎模型来促进纤维化过程，并观察到3区p16阳性肝细胞的积累。这些p16阳性细胞表现出多种衰老特征，其积累与肝纤维化的严重程度密切相关。研究显示，选择性清除p16阳性肝细胞可改善CCl4诱导的肝纤维化，推测是通过抑制肝星状细胞的激活实现的。单细胞转录组分析揭示，小鼠和人类肝细胞上调了LIFR信号通路的配体Ctf1或Lif。实验证明，给予LIFR配体可增强STAT3的磷酸化，而LIFR抑制剂则能挽救由衰老肝细胞分泌因子诱导的肝星状细胞促纤维化表型。这一发现为肝纤维化的管理提供了潜在的治疗见解。

### 第二部分 AI 大师评价

本研究深入探讨了衰老相关肝纤维化的细胞生物学机制，揭示了p16阳性衰老肝细胞通过分泌因子驱动肝脏纤维化的核心作用。研究通过CCl4模型及单细胞测序技术，成功识别出LIFR信号通路（及其配体Ctf1和Lif）是连接肝细胞衰老与肝星状细胞活化的关键分子桥梁。该研究不仅明确了衰老细胞作为纤维化启动者的地位，还证实了通过选择性清除衰老细胞或阻断LIFR通路来干预肝纤维化的治疗潜力，具有重要的临床转化价值。

---

## 5. 空间表型组学揭示致癌物暴露与否的小鼠肺腺癌癌前病变具有截然不同的分子与免疫演化特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580978)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41580978
**DOI：** 10.1002/advs.202512597

### 第一部分 原文与翻译

**英文原标题：** Spatial Profiling Reveals Distinct Molecular and Immune Evolution of Mouse Lung Adenocarcinoma Precancers with or Without Carcinogen Exposure.

> **英文摘要：**
> Tumor evolution involves genetic, transcriptional, and phenotypic alterations that shape cancer cell behavior and interactions with the microenvironment. While single-cell technologies have advanced our understanding of this process, spatial dynamics remain incompletely characterized. Here, whole-exome sequencing (WES), imaging mass cytometry (IMC), and spatial transcriptomics (ST) were integrated to study molecular evolution and immune responses in two lung adenocarcinoma (LUAD) mouse models: a genetically engineered model (129S4/Sv-Kras, termed 129S4 K) and a carcinogen-induced precancer model (129S4 U). Compared to 129S4 K, 129S4 U tumors exhibited higher mutational, neoantigen but lower copy number variation (CNV) burdens at matched developmental timepoints, consistent with findings of higher mutational burden in human smoking-related LUAD than nonsmoking LUAD. We profiled over 1.4 million spatial single cells from 284 IMC regions of interest and 51,531 spatial transcriptomic spots from 156 lesions across 141 mice. Macrophage abundance increased with tumor progression, while CD8 T-cell and B-cell densities declined in late-stage LUAD. 129S4 U showed greater immune infiltration in both tumor and adjacent normal tissue, higher T-cell cytotoxicity signature score in line with its higher mutational and neoantigen burdens. LUAD progression was marked by early morphological shifts and late-stage changes in cell states and interactions. These data define spatial and genetic landscapes of LUAD development and provide a framework for investigating immune evolution and therapeutic strategies in early carcinogenesis.

> **中文摘要：**
> 肿瘤演变涉及遗传、转录和表型改变，这些改变塑造了癌细胞的行为及其与微环境的相互作用。虽然单细胞技术增进了我们对这一过程的理解，但空间动力学特征仍未得到完全表征。本研究整合了全外显子组测序 (WES)、成像质谱流式技术 (IMC) 和空间转录组学 (ST)，以研究两种肺腺癌 (LUAD) 小鼠模型的分子演变和免疫反应：一种是基因工程模型 (129S4/Sv-Kras，简称 129S4 K)，另一种是致癌物诱导的癌前病变模型 (129S4 U)。与 129S4 K 相比，在相匹配的发育时间点，129S4 U 肿瘤表现出更高的突变和新抗原负荷，但拷贝数变异 (CNV) 负荷较低，这与人类吸烟相关 LUAD 比非吸烟 LUAD 具有更高突变负荷的发现一致。我们对来自 141 只小鼠的 156 个病灶、284 个 IMC 感兴趣区域中超过 140 万个空间单细胞以及 51,531 个空间转录组位点进行了分析。结果显示，巨噬细胞丰度随肿瘤进展而增加，而 CD8 T 细胞和 B 细胞密度在晚期 LUAD 中下降。129S4 U 在肿瘤和邻近正常组织中均表现出更强的免疫浸润，以及更高的 T 细胞细胞毒性特征评分，这与其较高的突变和新抗原负荷相一致。LUAD 的进展以早期形态转变和晚期细胞状态及相互作用的变化为特征。这些数据定义了 LUAD 发展的空间和遗传图谱，并为研究早期癌变过程中的免疫演化和治疗策略提供了一个框架。

### 第二部分 AI 大师评价

该研究通过整合全外显子组测序、成像质谱流式和空间转录组学等多组学技术，系统地对比了致癌物暴露对肺腺癌早期演化的时空影响。核心发现揭示了环境暴露（致癌物）相较于单一基因驱动更能显著提升突变负荷并重塑免疫微环境，这为理解人类吸烟相关肺癌的免疫特征提供了重要生物学证据。研究通过对海量单细胞层面的空间位置与功能的精准刻画，描绘了从癌前病变到晚期肺癌的细胞互作演变规律，为肺腺癌的早期预警和精准免疫干预提供了高分辨率的时空图谱。

---

## 6. 肿瘤微环境激活的放射增敏型CuS/LDH探针的原位合成，用于光声成像引导的放射治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580975)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41580975
**DOI：** 10.1002/advs.202522370

### 第一部分 原文与翻译

**英文原标题：** In Situ Synthesis of a Tumor Microenvironment-Activated Radiosensitizing CuS/LDH Probe for Photoacoustic Imaging-Guided Radiotherapy.

> **英文摘要：**
> The efficient delivery of theranostic nanoprobes to tumor sites remains a major challenge, often hindering precise tumor imaging and effective treatment. In this study, we present a novel strategy for the in situ generation of imaging and radiosensitizing nanoprobes inside tumors, enabling responsive photoacoustic imaging and targeted radiotherapy. The designed organic-inorganic hybrid nanoprobe is composed of a copper-based layered double hydroxide (Cu-LDH) intercalated with the near-infrared organic dye IR-806, serving as a photoacoustic imaging agent (designated as CAL-IR). Upon exposure to hydrogen sulfide (HS) in colorectal tumor microenvironments, the nanoprobe undergoes activation and transforms in situ into copper sulfide (Cu  S) nanoparticles. The newly formed Cu  S/LDH heterojunction nanostructure exhibits significantly enhanced near-infrared absorption, while concurrently promoting radiotherapy efficacy through multiple mechanisms: consumption of endogenous HS, reduction of X-ray attenuation, and intrinsic radiosensitization. This unique system allows high-contrast photoacoustic imaging and, consequently, achieves improved radiotherapy outcomes in mouse models of colorectal cancer, with minimal off-target effects. These results underscore the promising clinical potential of CAL-IR for precision tumor imaging and enhanced radiotherapy.

> **中文摘要：**
> 诊疗纳米探针向肿瘤部位的高效递送仍然是一个重大挑战，通常阻碍了精准的肿瘤成像和有效的治疗。在本研究中，我们提出了一种在肿瘤内部原位生成成像和放射增敏纳米探针的新策略，从而实现响应式光声成像和靶向放射治疗。所设计的有机-无机杂化纳米探针由插层了近红外有机染料IR-806的铜基层状双氢氧化物（Cu-LDH）组成，作为光声成像剂（命名为CAL-IR）。在暴露于结直肠肿瘤微环境中的硫化氢（H2S）后，该纳米探针发生激活并在原位转化为硫化铜（Cu2S）纳米颗粒。新形成的Cu2S/LDH异质结纳米结构表现出显著增强的近红外吸收，同时通过多种机制提升放射治疗效果：消耗内源性H2S、减少X射线衰减以及固有的放射增敏作用。该独特系统实现了高对比度的光声成像，并因此在结直肠癌小鼠模型中获得了改善的放射治疗结果，且脱靶效应极小。这些结果强调了CAL-IR在精准肿瘤成像和增强放射治疗方面具有广阔的临床应用潜力。

### 第二部分 AI 大师评价

本研究创新性地提出了一种利用肿瘤微环境内源性硫化氢（H2S）触发纳米探针原位转化的策略，成功构建了具有诊疗一体化功能的Cu2S/LDH异质结探针。该方法不仅通过原位合成克服了传统探针递送效率低的问题，还通过消耗H2S和降低X射线衰减等多重机制协同增强了放疗效果。实验在小鼠模型中验证了其卓越的成像对比度和抗肿瘤效力，且安全性良好，为结直肠癌的精准影像引导放疗提供了极具前景的临床转化方向。

---

## 7. 烷基三苯基膦与心磷脂结合诱发癌细胞坏死

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580973)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41580973
**DOI：** 10.1002/advs.202510237

### 第一部分 原文与翻译

**英文原标题：** Alkyltriphenylphosphonium Binding to Cardiolipin Triggers Oncosis in Cancer Cells.

> **英文摘要：**
> Mitochondria, pivotal for cellular bioenergetics and signaling, are attractive targets for cancer therapy. Triphenylphosphonium (TPP) is a widely used mitochondrial-targeting ligand, yet its intrinsic bioactivity and mechanism remain underexplored. Here we demonstrate that alkylated TPP derivatives exhibit chain length-dependent anticancer activity, with TPP-C showing superior efficacy both in vitro and in vivo. Mechanistically, TPP-C selectively binds to cardiolipin, a key phospholipid in the inner mitochondrial membrane, through electrostatic and hydrophobic interactions, as validated by biolayer interferometry, competitive binding assays, and molecular dynamics simulations. This binding impairs cardiolipin function, leading to mitochondrial membrane potential collapse, adenosine triphosphate depletion, metabolic reprogramming, and ultimately mitochondrial dysfunction. Intriguingly, TPP-C induces oncosis in cancer cells, rather than apoptosis or autophagy, by activating the endoplasmic reticulum stress pathway. These findings reveal a novel bioactive mechanism for TPP beyond its intrinsic mitochondrial targeting property, providing a foundation for next-generation mitochondrial-targeted anticancer strategies that could precisely modulate mitochondrial functions.

> **中文摘要：**
> 线粒体对细胞生物能量学和信号传导至关重要，是癌症治疗中极具吸引力的靶点。三苯基膦（TPP）是一种广泛使用的线粒体靶向配体，但其内在的生物活性和机制仍有待深入探索。在此，我们证明烷基化 TPP 衍生物表现出链长依赖性的抗癌活性，其中 TPP-C 在体内和体外均显示出卓越的功效。从机制上讲，TPP-C 通过静电和疏水相互作用选择性地与心磷脂（线粒体内膜中的一种关键磷脂）结合，这一点已通过生物层干涉技术、竞争性结合实验和分子动力学模拟得到验证。这种结合损害了心磷脂的功能，导致线粒体膜电位崩溃、三磷酸腺苷耗竭、代谢重编程，并最终导致线粒体功能障碍。有趣的是，TPP-C 通过激活内质网应激途径诱导癌细胞发生坏死（Oncosis），而非凋亡或自噬。这些发现揭示了 TPP 在其固有的线粒体靶向特性之外的一种新型生物活性机制，为能够精准调节线粒体功能的下一代线粒体靶向抗癌策略奠定了基础。

### 第二部分 AI 大师评价

本研究深入探讨了常用线粒体靶向配体TPP的内在抗癌机制，发现烷基化TPP衍生物（尤其是TPP-C）能通过静电与疏水作用特异性结合线粒体内膜的心磷脂。研究揭示了该结合会导致线粒体功能全面崩溃，并通过激活内质网应激途径诱导癌细胞发生非典型的坏死（Oncosis）而非凋亡。这一发现打破了TPP仅作为惰性载体的传统认知，为开发能够精准调控线粒体功能的下一代抗癌药物提供了重要的理论依据和新靶点。

---

## 8. 供体T细胞中SOCS1的缺失通过驱动趋化因子依赖的促炎免疫微环境加重肠道移植物抗宿主病

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41580972)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41580972
**DOI：** 10.1002/advs.202513735

### 第一部分 原文与翻译

**英文原标题：** Loss of SOCS1 in Donor T Cells Exacerbates Intestinal GVHD by Driving a Chemokine-Dependent Pro-Inflammatory Immune Microenvironment.

> **英文摘要：**
> Acute graft-versus-host disease (aGVHD) of the gastrointestinal tract is a frequent and often fatal complication of allogeneic hematopoietic stem cell transplantation. Suppressor of Cytokine Signaling 1 (SOCS1) is a key regulator of T cell pathogenicity, yet its role in aGVHD remains unclear. Using T cell-specific Socs1 knockout models, we show that Socs1 loss intrinsically drives pro-inflammatory T cell differentiation independent of antigen stimulation, with the strongest effects observed in CD8 T cells. Mechanistically, Socs1 deficiency activates a STAT1/2-dependent transcriptional program, inducing Ccl5 expression, monocyte recruitment, and M1-like macrophage polarization in peripheral lymphoid organs at steady state. After transplantation, Socs1-deficient T cells display enhanced infiltration into intestinal crypts, accompanied by increased CD8 T cell effector function, monocyte accumulation, and inflammatory macrophage polarization in target tissues. These changes promote tissue injury and impair regeneration, resulting in lethal aGVHD. Importantly, JAK1/2 inhibition with ruxolitinib reverses these pathogenic effects. Clinically, high SOCS1 expression in donor-derived CD8 T cells correlates with reduced aGVHD incidence. Together, our findings identify SOCS1 as a predictive biomarker and a potential therapeutic target for personalized aGVHD prophylaxis.

> **中文摘要：**
> 胃肠道急性移植物抗宿主病（aGVHD）是异基因造血干细胞移植中一种常见且往往致命的并发症。细胞因子信号转导抑制因子1（SOCS1）是T细胞致病性的关键调节因子，但其在aGVHD中的作用尚不清楚。利用T细胞特异性Socs1敲除模型，我们证明Socs1缺失可内源性驱动促炎T细胞分化（且独立于抗原刺激），其中在CD8+ T细胞中观察到的效果最强。从机制上讲，Socs1缺陷激活了STAT1/2依赖性转录程序，在稳态下的外周淋巴器官中诱导Ccl5表达、单核细胞招募和M1样巨噬细胞极化。移植后，Socs1缺陷型T细胞在肠隐窝中的浸润增强，并伴有靶组织中CD8+ T细胞效应功能增强、单核细胞积累和炎症巨噬细胞极化。这些变化促进了组织损伤并损害了再生，导致致死性aGVHD。重要的是，使用芦可替尼（ruxolitinib）抑制JAK1/2可逆转这些致病效应。临床上，供体来源CD8+ T细胞中SOCS1的高表达与aGVHD发生率降低相关。总之，我们的研究结果将SOCS1确定为个性化aGVHD预防的预测性生物标志物和潜在治疗靶点。

### 第二部分 AI 大师评价

本研究深入探讨了SOCS1在调节供体T细胞致病性及急性移植物抗宿主病（aGVHD）微环境中的核心作用。通过T细胞特异性敲除模型，研究揭示了SOCS1缺失如何通过STAT1/2通路触发Ccl5依赖的单核细胞招募和M1型巨噬细胞极化，进而加剧肠道损伤并抑制组织修复。该发现不仅阐明了aGVHD发病的新型免疫病理机制，还通过芦可替尼的有效干预实验及临床相关性分析，为aGVHD的精准预防和风险分层提供了强有力的生物标志物及潜在治疗靶点。

---

速递结束，祝您工作愉快！